GeneLink's Recent News Reviewed by Larry Oakley of WallStreetCorner.com
April 25, 2002

MARGATE, NJ-(Business Wire) April 25, 2002, GeneLink BioSciences, Inc. (OTCBB:GNLK) announced today that Larry Oakley has posted his analysis of the recent signing of a Letter of  Intent between GeneLink and Unicity NetworkÍ of Orem, Utah, one of the world's largest Direct Selling companies with over 250,000 independent distributors. 

Oakley comments , "...GeneLink's news release (4/18/2002) re: its letter of intent with Unicity Network,  is a clear indication that customized personal care products are now a reality through GNLK's breakthrough genetic profiling technology."

Further quotes, " Recent news releases by GeneLink indicate that it also has the ability & has applied for patents in the areas of nutrition, wellness, aging and obesity.  The key to GNLK's success will, in my opinion, be its distribution arrangements.  Here's how skin care products will be sold. The consumer will be offered a tailored formula specifically created for them - the value proposition is extraordinary and I expect the response will almost always be yes".

"The consumer will utilize GNLK's patented DNA collection kit.  By simply swabbing the inner cheek of the mouth and sending the collected sample to GNLK's labs, the consumer receives a customized skin care formulation expressly prepared in accordance with their individual DNA indications."

"GNLK is in an enviable position.  It doesn't have to do the selling.  It doesn't have to invest in inventory because it doesn't make the end products.  It just supplies its collection kits to the distribution company and does the computer profiling analysis on the DNA results which are sent to GNLK - all at an attractive profit".

"I interviewed GeneLink's CEO, John R. DePhillipo yesterday and am impressed with the direction he is taking the Company.  My opinion - what GNLK is doing could take this stock to at least $10 and John DePhillipo says he expects revenue from licensed distributors to begin in August 2002."

Click here for a complete copy of this informative article.

About GeneLink BioSciences, Inc.: GNLK is positioned to become a leading provider of genetic profiling technologies.  It developed a proprietary method for "genetic profiling" (patents pending) and will begin licensing this breakthrough technology to companies that market or manufacture products for the $100 billion plus nutraceutical, skin care, wellness and weight-loss industries.  GNLK has FDA clearance and patent issued for its non-invasive DNA Collection Kit.  Its DNA bank is located at the University of North Texas Health Science Center at Fort Worth, a 105 year old medical facility that guarantees the DNA storage.

Forward-Looking Statements:This press release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements whether as a result of new information, future developments or otherwise.

SOURCE: GeneLink BioSciences, Inc.